Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 193.66 Billion KRW | 1.17% |
| 2022 | 188.03 Billion KRW | -0.77% |
| 2021 | 189.48 Billion KRW | 12.28% |
| 2020 | 168.75 Billion KRW | -2.44% |
| 2019 | 172.97 Billion KRW | 280.09% |
| 2018 | 45.5 Billion KRW | 116.55% |
| 2017 | 21.01 Billion KRW | -83.29% |
| 2016 | 125.77 Billion KRW | -1.02% |
| 2015 | 127.06 Billion KRW | 5.6% |
| 2014 | 120.32 Billion KRW | 11.37% |
| 2013 | 108.04 Billion KRW | 6.49% |
| 2012 | 101.46 Billion KRW | -0.21% |
| 2011 | 101.67 Billion KRW | 9.59% |
| 2010 | 92.77 Billion KRW | 12.35% |
| 2009 | 82.57 Billion KRW | 3.67% |
| 2008 | 79.64 Billion KRW | 0.69% |
| 2007 | 79.1 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 65.83 Billion KRW | -4.13% |
| 2024 Q1 | 48.75 Billion KRW | -8.55% |
| 2023 Q3 | 46.54 Billion KRW | -6.12% |
| 2023 Q2 | 49.58 Billion KRW | 13.68% |
| 2023 Q4 | 53.31 Billion KRW | 14.53% |
| 2023 FY | 190.23 Billion KRW | 1.17% |
| 2023 Q1 | 43.61 Billion KRW | -5.06% |
| 2022 Q3 | 45.01 Billion KRW | -7.88% |
| 2022 Q2 | 48.86 Billion KRW | 1.34% |
| 2022 Q1 | 48.21 Billion KRW | -3.16% |
| 2022 FY | 188.03 Billion KRW | -0.77% |
| 2022 Q4 | 45.93 Billion KRW | 2.06% |
| 2021 Q4 | 49.79 Billion KRW | 5.43% |
| 2021 Q1 | 44.97 Billion KRW | -0.75% |
| 2021 Q2 | 47.34 Billion KRW | 5.27% |
| 2021 Q3 | 47.22 Billion KRW | -0.25% |
| 2021 FY | 189.48 Billion KRW | 12.28% |
| 2020 Q4 | 45.31 Billion KRW | 3.77% |
| 2020 FY | 168.75 Billion KRW | -2.44% |
| 2020 Q1 | 39.36 Billion KRW | -25.69% |
| 2020 Q2 | 40.4 Billion KRW | 2.66% |
| 2020 Q3 | 43.66 Billion KRW | 8.07% |
| 2019 Q2 | 39.66 Billion KRW | 6.49% |
| 2019 Q1 | 37.24 Billion KRW | 56.98% |
| 2019 Q4 | 52.97 Billion KRW | 22.94% |
| 2019 Q3 | 43.08 Billion KRW | 8.63% |
| 2019 FY | 172.97 Billion KRW | 280.09% |
| 2018 FY | 45.5 Billion KRW | 116.55% |
| 2018 Q4 | 23.72 Billion KRW | 219.35% |
| 2018 Q3 | 7.42 Billion KRW | 0.44% |
| 2018 Q2 | 7.39 Billion KRW | 6.39% |
| 2018 Q1 | 6.95 Billion KRW | -34.47% |
| 2017 Q2 | 3.18 Billion KRW | -89.95% |
| 2017 FY | 21.01 Billion KRW | -83.29% |
| 2017 Q1 | 31.62 Billion KRW | -73.25% |
| 2017 Q3 | 3.81 Billion KRW | 19.93% |
| 2017 Q4 | 10.61 Billion KRW | 178.19% |
| 2016 Q1 | 32.38 Billion KRW | 0.0% |
| 2016 Q3 | 2.74 Billion KRW | 39.83% |
| 2016 Q4 | 118.23 Billion KRW | 4204.55% |
| 2016 Q2 | 1.96 Billion KRW | -93.93% |
| 2016 FY | 125.77 Billion KRW | -1.02% |
| 2015 FY | 127.06 Billion KRW | 5.6% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 32.53 Billion KRW | 8.06% |
| 2015 Q2 | 30.11 Billion KRW | -5.13% |
| 2015 Q1 | 31.73 Billion KRW | -4.45% |
| 2014 Q2 | 29.34 Billion KRW | -0.03% |
| 2014 Q1 | 29.35 Billion KRW | 2.23% |
| 2014 FY | 120.32 Billion KRW | 11.37% |
| 2014 Q4 | 33.21 Billion KRW | 16.89% |
| 2014 Q3 | 28.41 Billion KRW | -3.15% |
| 2013 Q3 | 26.62 Billion KRW | -2.56% |
| 2013 Q4 | 28.7 Billion KRW | 7.85% |
| 2013 FY | 108.04 Billion KRW | 6.49% |
| 2013 Q1 | 25.39 Billion KRW | -18.38% |
| 2013 Q2 | 27.31 Billion KRW | 7.58% |
| 2012 Q4 | 31.11 Billion KRW | 28.78% |
| 2012 FY | 101.46 Billion KRW | -0.21% |
| 2012 Q1 | 22.86 Billion KRW | -22.17% |
| 2012 Q2 | 23.41 Billion KRW | 2.38% |
| 2012 Q3 | 24.15 Billion KRW | 3.19% |
| 2011 FY | 101.67 Billion KRW | 9.59% |
| 2011 Q4 | 29.38 Billion KRW | 18.83% |
| 2011 Q3 | 24.72 Billion KRW | 11.37% |
| 2011 Q2 | 22.2 Billion KRW | 2.95% |
| 2011 Q1 | 21.56 Billion KRW | -20.74% |
| 2010 Q2 | 18.82 Billion KRW | -16.2% |
| 2010 FY | 92.77 Billion KRW | 12.35% |
| 2010 Q4 | 27.21 Billion KRW | 12.14% |
| 2010 Q3 | 24.26 Billion KRW | 28.88% |
| 2010 Q1 | 22.46 Billion KRW | 13.15% |
| 2009 Q1 | 20.36 Billion KRW | 2.28% |
| 2009 Q2 | 21.01 Billion KRW | 3.18% |
| 2009 Q3 | 21.33 Billion KRW | 1.55% |
| 2009 Q4 | 19.85 Billion KRW | -6.95% |
| 2009 FY | 82.57 Billion KRW | 3.67% |
| 2008 Q3 | 19.97 Billion KRW | 0.69% |
| 2008 Q2 | 19.83 Billion KRW | -0.43% |
| 2008 Q1 | 19.92 Billion KRW | -3.76% |
| 2008 Q4 | 19.91 Billion KRW | -0.32% |
| 2008 FY | 79.64 Billion KRW | 0.69% |
| 2007 Q1 | 19.06 Billion KRW | 0.0% |
| 2007 Q4 | 20.7 Billion KRW | 10.24% |
| 2007 Q3 | 18.78 Billion KRW | -8.61% |
| 2007 Q2 | 20.54 Billion KRW | 7.77% |
| 2007 FY | 79.1 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -309.836% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 35.01% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 30.447% |
| HANDOK Inc. | 153.76 Billion KRW | -25.945% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -179.806% |
| Yuhan Corporation | 489.94 Billion KRW | 60.472% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 36.909% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -363.427% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 68.302% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -169.039% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -11.206% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -383.517% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -107.013% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -68.807% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -309.836% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -355.982% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -158.049% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -230.235% |
| JW Holdings Corporation | 301.25 Billion KRW | 35.715% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 25.787% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 52.61% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 18.939% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -51.691% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -183.503% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -194.539% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -10.712% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -309.836% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 22.262% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 65.444% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 18.939% |
| Yuhan Corporation | 489.94 Billion KRW | 60.472% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -178.779% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -245.63% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 18.939% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -53.224% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -63.825% |
| CKD Bio Corp. | 25.19 Billion KRW | -668.636% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 12.764% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -17.291% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -191.586% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -51.691% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 44.78% |
| Boryung Corporation | 285.16 Billion KRW | 32.086% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -121.223% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -11.206% |
| JW Lifescience Corporation | 20.26 Billion KRW | -855.817% |